Tue, Mar 14, 5:57 AM, Zacks
Myriad Genetics (MYGN) Launches EndoPredict Test in the US
Myriad Genetics, Inc. (MYGN), a leading name in the molecular diagnostics space, recently launched the EndoPredict test in the U.S. for patients with ER+ HER2 -- early-stage breast cancer.
Fri, Mar 10, 1:27 AM, Zacks
Why Is Myriad Genetics (MYGN) Up 15.8% Since the Last Earnings Report?
Myriad Genetics (MYGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.